Science Corp Raises $230M for Vision Restoration BCI

Science Corporation, a pioneering force in brain-computer interface (BCI) technology, has successfully closed a substantial $230 million Series C funding round. This significant capital infusion propels the company's valuation to an impressive $1.5 billion post-money, bringing its total raised capital to over $490 million. The investment underscores strong market confidence in Science Corp's ambitious mission to revolutionize vision restoration.

The funding was led by prominent venture capital firms, including Lightspeed Venture Partners and Khosla Ventures, alongside contributions from Y Combinator, Quiet Capital, and notably, IQT, the investment arm supporting the U.S. intelligence community. This diverse investor base highlights the broad appeal and strategic importance of Science Corp's technological advancements.

At the heart of Science Corp's innovation is its proprietary PRIMA implant. This microscopic BCI chip, smaller than a grain of rice, is designed for ocular implantation. When paired with specialized camera-equipped eyewear, PRIMA aims to restore functional sight for individuals afflicted with severe vision impairments, such as advanced macular degeneration. The technology represents a significant leap forward in addressing unmet needs within the ophthalmology and neurotechnology sectors.

Early clinical results have been exceptionally promising. In trials involving 47 participants across Europe and the United States, a remarkable 80% experienced meaningful improvements in visual acuity. These patients demonstrated the ability to discern letters, numbers, and words, indicating a tangible restoration of reading capabilities. Such outcomes are critical for improving quality of life and independence for those affected by vision loss.

With these encouraging trial results, Science Corp is actively pursuing regulatory approval. The company has submitted a CE mark application to the European Union, anticipating potential clearance by mid-2026. This milestone would position Science Corp as the first BCI company to bring a commercial product to market, setting a precedent for the industry. The funds will be instrumental in accelerating the commercial rollout of the PRIMA implant and further refining its capabilities as a leading vision restoration solution.

The development of advanced BCI technologies for medical applications is a rapidly expanding field. The global BCI market is projected to experience significant growth, driven by increasing demand for neuroprosthetics, therapeutic interventions for neurological disorders, and assistive technologies. Science Corp's focus on vision restoration taps into a critical area of medical need, with the potential to impact millions worldwide. The company's founder, Max Hodak, previously co-founded Neuralink, bringing a wealth of experience in developing cutting-edge neural interface systems to Science Corp.